{"id":8802,"date":"2025-08-23T02:56:05","date_gmt":"2025-08-23T00:56:05","guid":{"rendered":"https:\/\/rvh-synergie.org\/actualites\/la-fda-approuve-les-papzimeos-pour-les-adultes-atteints-de-papillomatose-respiratoire-recurrente\/"},"modified":"2025-08-23T02:56:07","modified_gmt":"2025-08-23T00:56:07","slug":"la-fda-approuve-les-papzimeos-pour-les-adultes-atteints-de-papillomatose-respiratoire-recurrente","status":"publish","type":"post","link":"https:\/\/rvh-synergie.org\/actualites\/la-fda-approuve-les-papzimeos-pour-les-adultes-atteints-de-papillomatose-respiratoire-recurrente\/","title":{"rendered":"La FDA approuve les papzimeos pour les adultes atteints de papillomatose respiratoire r\u00e9currente"},"content":{"rendered":"<div>\n<div class=\"article-gallery lightGallery\">\n<div data-thumb=\"https:\/\/scx1.b-cdn.net\/csz\/news\/tmb\/2025\/fda-approves-papzimeos.jpg\" data-src=\"https:\/\/scx2.b-cdn.net\/gfx\/news\/2025\/fda-approves-papzimeos.jpg\" data-sub-html=\"\">\n<figure class=\"article-img\">\n<\/figure><\/div>\n<\/div>\n<p>La Food and Drug Administration des \u00c9tats-Unis a approuv\u00e9 Papzimeos (ZopapoG\u00e8ne imadenovec-DRBA) pour le traitement des adultes atteints de papillomatose respiratoire r\u00e9currente (RRP).<\/p>\n<p>Papzimeos est une immunoth\u00e9rapie \u00e0 base de vecteur ad\u00e9novirale non r\u00e9plicante qui exprime un antig\u00e8ne de fusion compos\u00e9 de r\u00e9gions s\u00e9lectionn\u00e9es de prot\u00e9ines 6 et 11 de types de papillomavirus humain (HPV), la cause profonde du RRP. Papzimeos est administr\u00e9 par quatre injections sous-cutan\u00e9es sur une p\u00e9riode de 12 semaines.<\/p>\n<p>L&rsquo;approbation est bas\u00e9e sur un essai dans lequel la moiti\u00e9 des patients de l&rsquo;\u00e9tude (18 sur 35) ont obtenu une r\u00e9ponse compl\u00e8te, ne n\u00e9cessitant aucune intervention chirurgicale dans les 12 mois suivant le traitement par Papzimeos. Sur ces 18 patients, 15 ont continu\u00e9 \u00e0 montrer une r\u00e9ponse compl\u00e8te \u00e0 24 mois. Aucune toxicit\u00e9 limitant la dose n&rsquo;a \u00e9t\u00e9 signal\u00e9e avec Papzimeos et aucun \u00e9v\u00e9nement ind\u00e9sirable li\u00e9 au traitement sup\u00e9rieur \u00e0 la grade 2 n&rsquo;a \u00e9t\u00e9 observ\u00e9.<\/p>\n<p>\u00ab\u00a0Depuis plus d&rsquo;un si\u00e8cle, puisque RRP a \u00e9t\u00e9 reconnu pour la premi\u00e8re fois comme une maladie distincte, les patients ont d\u00fb s&rsquo;appuyer sur des chirurgies r\u00e9p\u00e9t\u00e9es pour g\u00e9rer cette condition implacable\u00a0\u00bb, a d\u00e9clar\u00e9 Helen Sabzevari, Ph.D., pr\u00e9sidente et chef de la direction de Precigen, dans un communiqu\u00e9. \u00ab\u00a0Aujourd&rsquo;hui marque un tournant historique. Avec l&rsquo;approbation historique de la FDA de Papzimeos et de Broad Label, tous les patients RRP adultes sont d\u00e9sormais \u00e9ligibles pour l&rsquo;acc\u00e8s \u00e0 la premi\u00e8re et la seule th\u00e9rapie approuv\u00e9e qui cible la cause profonde de la maladie.\u00a0\u00bb<\/p>\n<p>L&rsquo;approbation de Papzimeos a \u00e9t\u00e9 accord\u00e9e \u00e0 la pr\u00e9ciguration.<\/p>\n<p>                                        <!-- print only --><\/p><\/div>\n","protected":false},"excerpt":{"rendered":"<p>La Food and Drug Administration des \u00c9tats-Unis a approuv\u00e9 Papzimeos (ZopapoG\u00e8ne imadenovec-DRBA) pour le traitement<\/p>\n","protected":false},"author":1,"featured_media":8803,"comment_status":"closed","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[86],"tags":[690,321,282,447,49,6390,6389,8,970,2441],"class_list":["post-8802","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-les-maladies","tag-adultes","tag-approuve","tag-atteints","tag-fda","tag-les","tag-papillomatose","tag-papzimeos","tag-pour","tag-recurrente","tag-respiratoire","generate-columns","tablet-grid-50","mobile-grid-100","grid-parent","grid-50","resize-featured-image"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v23.4 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>La FDA approuve les papzimeos pour les adultes atteints de papillomatose respiratoire r\u00e9currente - RVH-Synergie.org<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/rvh-synergie.org\/actualites\/la-fda-approuve-les-papzimeos-pour-les-adultes-atteints-de-papillomatose-respiratoire-recurrente\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"La FDA approuve les papzimeos pour les adultes atteints de papillomatose respiratoire r\u00e9currente - RVH-Synergie.org\" \/>\n<meta property=\"og:description\" content=\"La Food and Drug Administration des \u00c9tats-Unis a approuv\u00e9 Papzimeos (ZopapoG\u00e8ne imadenovec-DRBA) pour le traitement\" \/>\n<meta property=\"og:url\" content=\"https:\/\/rvh-synergie.org\/actualites\/la-fda-approuve-les-papzimeos-pour-les-adultes-atteints-de-papillomatose-respiratoire-recurrente\/\" \/>\n<meta property=\"og:site_name\" content=\"RVH-Synergie\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-23T00:56:05+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-08-23T00:56:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2025\/08\/1755910565_La-FDA-approuve-les-papzimeos-pour-les-adultes-atteints-de.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1280\" \/>\n\t<meta property=\"og:image:height\" content=\"853\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Charles Martinez\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Charles Martinez\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/la-fda-approuve-les-papzimeos-pour-les-adultes-atteints-de-papillomatose-respiratoire-recurrente\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/la-fda-approuve-les-papzimeos-pour-les-adultes-atteints-de-papillomatose-respiratoire-recurrente\/\"},\"author\":{\"name\":\"Charles Martinez\",\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/#\/schema\/person\/aa5ea98671fb4e8620f488a0795d2560\"},\"headline\":\"La FDA approuve les papzimeos pour les adultes atteints de papillomatose respiratoire r\u00e9currente\",\"datePublished\":\"2025-08-23T00:56:05+00:00\",\"dateModified\":\"2025-08-23T00:56:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/la-fda-approuve-les-papzimeos-pour-les-adultes-atteints-de-papillomatose-respiratoire-recurrente\/\"},\"wordCount\":294,\"publisher\":{\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/#organization\"},\"image\":{\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/la-fda-approuve-les-papzimeos-pour-les-adultes-atteints-de-papillomatose-respiratoire-recurrente\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2025\/08\/1755910565_La-FDA-approuve-les-papzimeos-pour-les-adultes-atteints-de.jpg\",\"keywords\":[\"adultes\",\"approuve\",\"atteints\",\"FDA\",\"Les\",\"papillomatose\",\"papzimeos\",\"pour\",\"r\u00e9currente\",\"respiratoire\"],\"articleSection\":[\"Les maladies\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/la-fda-approuve-les-papzimeos-pour-les-adultes-atteints-de-papillomatose-respiratoire-recurrente\/\",\"url\":\"https:\/\/rvh-synergie.org\/actualites\/la-fda-approuve-les-papzimeos-pour-les-adultes-atteints-de-papillomatose-respiratoire-recurrente\/\",\"name\":\"La FDA approuve les papzimeos pour les adultes atteints de papillomatose respiratoire r\u00e9currente - RVH-Synergie.org\",\"isPartOf\":{\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/la-fda-approuve-les-papzimeos-pour-les-adultes-atteints-de-papillomatose-respiratoire-recurrente\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/la-fda-approuve-les-papzimeos-pour-les-adultes-atteints-de-papillomatose-respiratoire-recurrente\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2025\/08\/1755910565_La-FDA-approuve-les-papzimeos-pour-les-adultes-atteints-de.jpg\",\"datePublished\":\"2025-08-23T00:56:05+00:00\",\"dateModified\":\"2025-08-23T00:56:07+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/la-fda-approuve-les-papzimeos-pour-les-adultes-atteints-de-papillomatose-respiratoire-recurrente\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/rvh-synergie.org\/actualites\/la-fda-approuve-les-papzimeos-pour-les-adultes-atteints-de-papillomatose-respiratoire-recurrente\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/la-fda-approuve-les-papzimeos-pour-les-adultes-atteints-de-papillomatose-respiratoire-recurrente\/#primaryimage\",\"url\":\"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2025\/08\/1755910565_La-FDA-approuve-les-papzimeos-pour-les-adultes-atteints-de.jpg\",\"contentUrl\":\"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2025\/08\/1755910565_La-FDA-approuve-les-papzimeos-pour-les-adultes-atteints-de.jpg\",\"width\":1280,\"height\":853,\"caption\":\"La FDA approuve les papzimeos pour les adultes atteints de papillomatose respiratoire r\u00e9currente\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/la-fda-approuve-les-papzimeos-pour-les-adultes-atteints-de-papillomatose-respiratoire-recurrente\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/rvh-synergie.org\/actualites\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"La FDA approuve les papzimeos pour les adultes atteints de papillomatose respiratoire r\u00e9currente\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/#website\",\"url\":\"https:\/\/rvh-synergie.org\/actualites\/\",\"name\":\"RVH-Synergie.org\",\"description\":\"RVH-Synergie, site ind\u00e9pendant d&#039;informations sur la prise en charge des addictions.\",\"publisher\":{\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/rvh-synergie.org\/actualites\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/#organization\",\"name\":\"RVH-Synergie.org\",\"url\":\"https:\/\/rvh-synergie.org\/actualites\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/09\/favicon.png\",\"contentUrl\":\"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/09\/favicon.png\",\"width\":512,\"height\":512,\"caption\":\"RVH-Synergie.org\"},\"image\":{\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/#\/schema\/person\/aa5ea98671fb4e8620f488a0795d2560\",\"name\":\"Charles Martinez\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/09\/charles-martinez-scaled.jpg\",\"contentUrl\":\"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/09\/charles-martinez-scaled.jpg\",\"caption\":\"Charles Martinez\"},\"description\":\"Bonjour, je m'appelle Charles Martinez, r\u00e9dacteur passionn\u00e9 pour le m\u00e9dia RVH-synergie.org, d\u00e9di\u00e9 aux addictions et aux maladies. Depuis plus de dix ans, j'explore et rapporte les histoires poignantes des individus confront\u00e9s \u00e0 ces d\u00e9fis, tout en sensibilisant le public aux traitements novateurs et aux progr\u00e8s scientifiques dans ce domaine. Mon engagement r\u00e9side dans l'espoir de cr\u00e9er une communaut\u00e9 inform\u00e9e et empathique, pr\u00eate \u00e0 soutenir ceux qui luttent contre ces \u00e9preuves.\",\"sameAs\":[\"https:\/\/rvh-synergie.org\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"La FDA approuve les papzimeos pour les adultes atteints de papillomatose respiratoire r\u00e9currente - RVH-Synergie.org","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/rvh-synergie.org\/actualites\/la-fda-approuve-les-papzimeos-pour-les-adultes-atteints-de-papillomatose-respiratoire-recurrente\/","og_locale":"fr_FR","og_type":"article","og_title":"La FDA approuve les papzimeos pour les adultes atteints de papillomatose respiratoire r\u00e9currente - RVH-Synergie.org","og_description":"La Food and Drug Administration des \u00c9tats-Unis a approuv\u00e9 Papzimeos (ZopapoG\u00e8ne imadenovec-DRBA) pour le traitement","og_url":"https:\/\/rvh-synergie.org\/actualites\/la-fda-approuve-les-papzimeos-pour-les-adultes-atteints-de-papillomatose-respiratoire-recurrente\/","og_site_name":"RVH-Synergie","article_published_time":"2025-08-23T00:56:05+00:00","article_modified_time":"2025-08-23T00:56:07+00:00","og_image":[{"width":1280,"height":853,"url":"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2025\/08\/1755910565_La-FDA-approuve-les-papzimeos-pour-les-adultes-atteints-de.jpg","type":"image\/jpeg"}],"author":"Charles Martinez","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Charles Martinez","Dur\u00e9e de lecture estim\u00e9e":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/rvh-synergie.org\/actualites\/la-fda-approuve-les-papzimeos-pour-les-adultes-atteints-de-papillomatose-respiratoire-recurrente\/#article","isPartOf":{"@id":"https:\/\/rvh-synergie.org\/actualites\/la-fda-approuve-les-papzimeos-pour-les-adultes-atteints-de-papillomatose-respiratoire-recurrente\/"},"author":{"name":"Charles Martinez","@id":"https:\/\/rvh-synergie.org\/actualites\/#\/schema\/person\/aa5ea98671fb4e8620f488a0795d2560"},"headline":"La FDA approuve les papzimeos pour les adultes atteints de papillomatose respiratoire r\u00e9currente","datePublished":"2025-08-23T00:56:05+00:00","dateModified":"2025-08-23T00:56:07+00:00","mainEntityOfPage":{"@id":"https:\/\/rvh-synergie.org\/actualites\/la-fda-approuve-les-papzimeos-pour-les-adultes-atteints-de-papillomatose-respiratoire-recurrente\/"},"wordCount":294,"publisher":{"@id":"https:\/\/rvh-synergie.org\/actualites\/#organization"},"image":{"@id":"https:\/\/rvh-synergie.org\/actualites\/la-fda-approuve-les-papzimeos-pour-les-adultes-atteints-de-papillomatose-respiratoire-recurrente\/#primaryimage"},"thumbnailUrl":"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2025\/08\/1755910565_La-FDA-approuve-les-papzimeos-pour-les-adultes-atteints-de.jpg","keywords":["adultes","approuve","atteints","FDA","Les","papillomatose","papzimeos","pour","r\u00e9currente","respiratoire"],"articleSection":["Les maladies"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/rvh-synergie.org\/actualites\/la-fda-approuve-les-papzimeos-pour-les-adultes-atteints-de-papillomatose-respiratoire-recurrente\/","url":"https:\/\/rvh-synergie.org\/actualites\/la-fda-approuve-les-papzimeos-pour-les-adultes-atteints-de-papillomatose-respiratoire-recurrente\/","name":"La FDA approuve les papzimeos pour les adultes atteints de papillomatose respiratoire r\u00e9currente - RVH-Synergie.org","isPartOf":{"@id":"https:\/\/rvh-synergie.org\/actualites\/#website"},"primaryImageOfPage":{"@id":"https:\/\/rvh-synergie.org\/actualites\/la-fda-approuve-les-papzimeos-pour-les-adultes-atteints-de-papillomatose-respiratoire-recurrente\/#primaryimage"},"image":{"@id":"https:\/\/rvh-synergie.org\/actualites\/la-fda-approuve-les-papzimeos-pour-les-adultes-atteints-de-papillomatose-respiratoire-recurrente\/#primaryimage"},"thumbnailUrl":"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2025\/08\/1755910565_La-FDA-approuve-les-papzimeos-pour-les-adultes-atteints-de.jpg","datePublished":"2025-08-23T00:56:05+00:00","dateModified":"2025-08-23T00:56:07+00:00","breadcrumb":{"@id":"https:\/\/rvh-synergie.org\/actualites\/la-fda-approuve-les-papzimeos-pour-les-adultes-atteints-de-papillomatose-respiratoire-recurrente\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/rvh-synergie.org\/actualites\/la-fda-approuve-les-papzimeos-pour-les-adultes-atteints-de-papillomatose-respiratoire-recurrente\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/rvh-synergie.org\/actualites\/la-fda-approuve-les-papzimeos-pour-les-adultes-atteints-de-papillomatose-respiratoire-recurrente\/#primaryimage","url":"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2025\/08\/1755910565_La-FDA-approuve-les-papzimeos-pour-les-adultes-atteints-de.jpg","contentUrl":"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2025\/08\/1755910565_La-FDA-approuve-les-papzimeos-pour-les-adultes-atteints-de.jpg","width":1280,"height":853,"caption":"La FDA approuve les papzimeos pour les adultes atteints de papillomatose respiratoire r\u00e9currente"},{"@type":"BreadcrumbList","@id":"https:\/\/rvh-synergie.org\/actualites\/la-fda-approuve-les-papzimeos-pour-les-adultes-atteints-de-papillomatose-respiratoire-recurrente\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/rvh-synergie.org\/actualites\/"},{"@type":"ListItem","position":2,"name":"La FDA approuve les papzimeos pour les adultes atteints de papillomatose respiratoire r\u00e9currente"}]},{"@type":"WebSite","@id":"https:\/\/rvh-synergie.org\/actualites\/#website","url":"https:\/\/rvh-synergie.org\/actualites\/","name":"RVH-Synergie.org","description":"RVH-Synergie, site ind\u00e9pendant d&#039;informations sur la prise en charge des addictions.","publisher":{"@id":"https:\/\/rvh-synergie.org\/actualites\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/rvh-synergie.org\/actualites\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/rvh-synergie.org\/actualites\/#organization","name":"RVH-Synergie.org","url":"https:\/\/rvh-synergie.org\/actualites\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/rvh-synergie.org\/actualites\/#\/schema\/logo\/image\/","url":"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/09\/favicon.png","contentUrl":"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/09\/favicon.png","width":512,"height":512,"caption":"RVH-Synergie.org"},"image":{"@id":"https:\/\/rvh-synergie.org\/actualites\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/rvh-synergie.org\/actualites\/#\/schema\/person\/aa5ea98671fb4e8620f488a0795d2560","name":"Charles Martinez","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/rvh-synergie.org\/actualites\/#\/schema\/person\/image\/","url":"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/09\/charles-martinez-scaled.jpg","contentUrl":"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/09\/charles-martinez-scaled.jpg","caption":"Charles Martinez"},"description":"Bonjour, je m'appelle Charles Martinez, r\u00e9dacteur passionn\u00e9 pour le m\u00e9dia RVH-synergie.org, d\u00e9di\u00e9 aux addictions et aux maladies. Depuis plus de dix ans, j'explore et rapporte les histoires poignantes des individus confront\u00e9s \u00e0 ces d\u00e9fis, tout en sensibilisant le public aux traitements novateurs et aux progr\u00e8s scientifiques dans ce domaine. Mon engagement r\u00e9side dans l'espoir de cr\u00e9er une communaut\u00e9 inform\u00e9e et empathique, pr\u00eate \u00e0 soutenir ceux qui luttent contre ces \u00e9preuves.","sameAs":["https:\/\/rvh-synergie.org\/"]}]}},"_links":{"self":[{"href":"https:\/\/rvh-synergie.org\/actualites\/wp-json\/wp\/v2\/posts\/8802","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/rvh-synergie.org\/actualites\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/rvh-synergie.org\/actualites\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/rvh-synergie.org\/actualites\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/rvh-synergie.org\/actualites\/wp-json\/wp\/v2\/comments?post=8802"}],"version-history":[{"count":0,"href":"https:\/\/rvh-synergie.org\/actualites\/wp-json\/wp\/v2\/posts\/8802\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/rvh-synergie.org\/actualites\/wp-json\/wp\/v2\/media\/8803"}],"wp:attachment":[{"href":"https:\/\/rvh-synergie.org\/actualites\/wp-json\/wp\/v2\/media?parent=8802"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/rvh-synergie.org\/actualites\/wp-json\/wp\/v2\/categories?post=8802"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/rvh-synergie.org\/actualites\/wp-json\/wp\/v2\/tags?post=8802"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}